http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 30 Oct 2025 16:16:23 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/NLS+Pharmaceutics+and+Kadimastem+complete+merger+as+NewcelX/25530809.html <p>NLS Pharmaceutics Ltd. (NASDAQ: NLSP) and Kadimastem Ltd. completed their merger transaction on October 30, 2025, with the combined company renamed NewcelX Ltd. (NASDAQ: NCEL). The new entity will begin trading on the Nasdaq Capital Market on October 31, 2025, under the ticker symbol "NCEL."</p><p>Under the merger agreement dated November 4, 2024, Kadimastem shareholders received 0.706 NewcelX common shares for each Kadimastem ordinary share. The exchange ratio reflects a 1-for-10 reverse share split implemented by NewcelX in connection with the merger.</p><p>Following the merger completion, NewcelX has approximately 4,558,378 common shares outstanding, 1,060,574 common shares issuable upon exercise of pre-funded warrants, http://www.streetinsider.com/Corporate+News/NLS+Pharmaceutics+and+Kadimastem+complete+merger+as+NewcelX/25530809.html Thu, 30 Oct 2025 16:16:23 -0500 NCEL NLS NLSP NLSPW http://www.streetinsider.com/Corporate+News/NLS+Pharmaceutics+and+Kadimastem+complete+merger+as+NewcelX/25530809.html <p>NLS Pharmaceutics Ltd. (NASDAQ: NLSP) and Kadimastem Ltd. completed their merger transaction on October 30, 2025, with the combined company renamed NewcelX Ltd. (NASDAQ: NCEL). The new entity will begin trading on the Nasdaq Capital Market on October 31, 2025, under the ticker symbol "NCEL."</p><p>Under the merger agreement dated November 4, 2024, Kadimastem shareholders received 0.706 NewcelX common shares for each Kadimastem ordinary share. The exchange ratio reflects a 1-for-10 reverse share split implemented by NewcelX in connection with the merger.</p><p>Following the merger completion, NewcelX has approximately 4,558,378 common shares outstanding, 1,060,574 common shares issuable upon exercise of pre-funded warrants, http://www.streetinsider.com/Corporate+News/NLS+Pharmaceutics+and+Kadimastem+complete+merger+as+NewcelX/25530809.html Thu, 30 Oct 2025 16:16:23 -0500 NCEL NLS NLSP NLSPW http://www.streetinsider.com/Corporate+News/NLS+Pharmaceutics+and+Kadimastem+complete+merger+as+NewcelX/25530809.html <p>NLS Pharmaceutics Ltd. (NASDAQ: NLSP) and Kadimastem Ltd. completed their merger transaction on October 30, 2025, with the combined company renamed NewcelX Ltd. (NASDAQ: NCEL). The new entity will begin trading on the Nasdaq Capital Market on October 31, 2025, under the ticker symbol "NCEL."</p><p>Under the merger agreement dated November 4, 2024, Kadimastem shareholders received 0.706 NewcelX common shares for each Kadimastem ordinary share. The exchange ratio reflects a 1-for-10 reverse share split implemented by NewcelX in connection with the merger.</p><p>Following the merger completion, NewcelX has approximately 4,558,378 common shares outstanding, 1,060,574 common shares issuable upon exercise of pre-funded warrants, http://www.streetinsider.com/Corporate+News/NLS+Pharmaceutics+and+Kadimastem+complete+merger+as+NewcelX/25530809.html Thu, 30 Oct 2025 16:16:23 -0500 NCEL NLS NLSP NLSPW http://www.streetinsider.com/Corporate+News/NLS+Pharmaceutics+and+Kadimastem+complete+merger+as+NewcelX/25530809.html <p>NLS Pharmaceutics Ltd. (NASDAQ: NLSP) and Kadimastem Ltd. completed their merger transaction on October 30, 2025, with the combined company renamed NewcelX Ltd. (NASDAQ: NCEL). The new entity will begin trading on the Nasdaq Capital Market on October 31, 2025, under the ticker symbol "NCEL."</p><p>Under the merger agreement dated November 4, 2024, Kadimastem shareholders received 0.706 NewcelX common shares for each Kadimastem ordinary share. The exchange ratio reflects a 1-for-10 reverse share split implemented by NewcelX in connection with the merger.</p><p>Following the merger completion, NewcelX has approximately 4,558,378 common shares outstanding, 1,060,574 common shares issuable upon exercise of pre-funded warrants, http://www.streetinsider.com/Corporate+News/NLS+Pharmaceutics+and+Kadimastem+complete+merger+as+NewcelX/25530809.html Thu, 30 Oct 2025 16:16:23 -0500 NCEL NLS NLSP NLSPW http://www.streetinsider.com/Mergers+and+Acquisitions/NLS+Pharmaceutics+and+Kadimastem+complete+merger+as+NewcelX/25530809.html <p>NLS Pharmaceutics Ltd. (NASDAQ: NLSP) and Kadimastem Ltd. completed their merger transaction on October 30, 2025, with the combined company renamed NewcelX Ltd. (NASDAQ: NCEL). The new entity will begin trading on the Nasdaq Capital Market on October 31, 2025, under the ticker symbol "NCEL."</p><p>Under the merger agreement dated November 4, 2024, Kadimastem shareholders received 0.706 NewcelX common shares for each Kadimastem ordinary share. The exchange ratio reflects a 1-for-10 reverse share split implemented by NewcelX in connection with the merger.</p><p>Following the merger completion, NewcelX has approximately 4,558,378 common shares outstanding, 1,060,574 common shares issuable upon exercise of pre-funded warrants, http://www.streetinsider.com/Mergers+and+Acquisitions/NLS+Pharmaceutics+and+Kadimastem+complete+merger+as+NewcelX/25530809.html Thu, 30 Oct 2025 16:16:23 -0500 NCEL NLS NLSP NLSPW http://www.streetinsider.com/Mergers+and+Acquisitions/NLS+Pharmaceutics+and+Kadimastem+complete+merger+as+NewcelX/25530809.html <p>NLS Pharmaceutics Ltd. (NASDAQ: NLSP) and Kadimastem Ltd. completed their merger transaction on October 30, 2025, with the combined company renamed NewcelX Ltd. (NASDAQ: NCEL). The new entity will begin trading on the Nasdaq Capital Market on October 31, 2025, under the ticker symbol "NCEL."</p><p>Under the merger agreement dated November 4, 2024, Kadimastem shareholders received 0.706 NewcelX common shares for each Kadimastem ordinary share. The exchange ratio reflects a 1-for-10 reverse share split implemented by NewcelX in connection with the merger.</p><p>Following the merger completion, NewcelX has approximately 4,558,378 common shares outstanding, 1,060,574 common shares issuable upon exercise of pre-funded warrants, http://www.streetinsider.com/Mergers+and+Acquisitions/NLS+Pharmaceutics+and+Kadimastem+complete+merger+as+NewcelX/25530809.html Thu, 30 Oct 2025 16:16:23 -0500 NCEL NLS NLSP NLSPW http://www.streetinsider.com/Mergers+and+Acquisitions/NLS+Pharmaceutics+and+Kadimastem+complete+merger+as+NewcelX/25530809.html <p>NLS Pharmaceutics Ltd. (NASDAQ: NLSP) and Kadimastem Ltd. completed their merger transaction on October 30, 2025, with the combined company renamed NewcelX Ltd. (NASDAQ: NCEL). The new entity will begin trading on the Nasdaq Capital Market on October 31, 2025, under the ticker symbol "NCEL."</p><p>Under the merger agreement dated November 4, 2024, Kadimastem shareholders received 0.706 NewcelX common shares for each Kadimastem ordinary share. The exchange ratio reflects a 1-for-10 reverse share split implemented by NewcelX in connection with the merger.</p><p>Following the merger completion, NewcelX has approximately 4,558,378 common shares outstanding, 1,060,574 common shares issuable upon exercise of pre-funded warrants, http://www.streetinsider.com/Mergers+and+Acquisitions/NLS+Pharmaceutics+and+Kadimastem+complete+merger+as+NewcelX/25530809.html Thu, 30 Oct 2025 16:16:23 -0500 NCEL NLS NLSP NLSPW http://www.streetinsider.com/Mergers+and+Acquisitions/NLS+Pharmaceutics+and+Kadimastem+complete+merger+as+NewcelX/25530809.html <p>NLS Pharmaceutics Ltd. (NASDAQ: NLSP) and Kadimastem Ltd. completed their merger transaction on October 30, 2025, with the combined company renamed NewcelX Ltd. (NASDAQ: NCEL). The new entity will begin trading on the Nasdaq Capital Market on October 31, 2025, under the ticker symbol "NCEL."</p><p>Under the merger agreement dated November 4, 2024, Kadimastem shareholders received 0.706 NewcelX common shares for each Kadimastem ordinary share. The exchange ratio reflects a 1-for-10 reverse share split implemented by NewcelX in connection with the merger.</p><p>Following the merger completion, NewcelX has approximately 4,558,378 common shares outstanding, 1,060,574 common shares issuable upon exercise of pre-funded warrants, http://www.streetinsider.com/Mergers+and+Acquisitions/NLS+Pharmaceutics+and+Kadimastem+complete+merger+as+NewcelX/25530809.html Thu, 30 Oct 2025 16:16:23 -0500 NCEL NLS NLSP NLSPW http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+Ltd.+and+Kadimastem+Ltd.+Announce+Completion+of+Merger/25530766.html <div class="xn-content"> <p class="prntac"><span>Combined Company Re-Named NewcelX Ltd.</span>, to Commence Trading on the Nasdaq Capital Market on <chron>October 31, 2025</chron> under the Ticker Symbol "NCEL"</p> <p> <span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location> and NESS ZIONA, Israel </span>, <span class="legendSpanClass"><chron>Oct. 30, 2025</chron></span> /PRNewswire/ -- </p> http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+Ltd.+and+Kadimastem+Ltd.+Announce+Completion+of+Merger/25530766.html Thu, 30 Oct 2025 16:15:00 -0500 NCEL NCEL NLS NLSP NLSPW O.23415075 http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+Ltd.+and+Kadimastem+Ltd.+Announce+Completion+of+Merger/25530766.html <div class="xn-content"> <p class="prntac"><span>Combined Company Re-Named NewcelX Ltd.</span>, to Commence Trading on the Nasdaq Capital Market on <chron>October 31, 2025</chron> under the Ticker Symbol "NCEL"</p> <p> <span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location> and NESS ZIONA, Israel </span>, <span class="legendSpanClass"><chron>Oct. 30, 2025</chron></span> /PRNewswire/ -- </p> http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+Ltd.+and+Kadimastem+Ltd.+Announce+Completion+of+Merger/25530766.html Thu, 30 Oct 2025 16:15:00 -0500 NCEL NCEL NLS NLSP NLSPW O.23415075 http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+Ltd.+and+Kadimastem+Ltd.+Announce+Completion+of+Merger/25530766.html <div class="xn-content"> <p class="prntac"><span>Combined Company Re-Named NewcelX Ltd.</span>, to Commence Trading on the Nasdaq Capital Market on <chron>October 31, 2025</chron> under the Ticker Symbol "NCEL"</p> <p> <span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location> and NESS ZIONA, Israel </span>, <span class="legendSpanClass"><chron>Oct. 30, 2025</chron></span> /PRNewswire/ -- </p> http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+Ltd.+and+Kadimastem+Ltd.+Announce+Completion+of+Merger/25530766.html Thu, 30 Oct 2025 16:15:00 -0500 NCEL NCEL NLS NLSP NLSPW O.23415075 http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+Ltd.+and+Kadimastem+Ltd.+Announce+Completion+of+Merger/25530766.html <div class="xn-content"> <p class="prntac"><span>Combined Company Re-Named NewcelX Ltd.</span>, to Commence Trading on the Nasdaq Capital Market on <chron>October 31, 2025</chron> under the Ticker Symbol "NCEL"</p> <p> <span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location> and NESS ZIONA, Israel </span>, <span class="legendSpanClass"><chron>Oct. 30, 2025</chron></span> /PRNewswire/ -- </p> http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+Ltd.+and+Kadimastem+Ltd.+Announce+Completion+of+Merger/25530766.html Thu, 30 Oct 2025 16:15:00 -0500 NCEL NCEL NLS NLSP NLSPW O.23415075 http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+Ltd.+and+Kadimastem+Ltd.+Announce+Completion+of+Merger/25530766.html <div class="xn-content"> <p class="prntac"><span>Combined Company Re-Named NewcelX Ltd.</span>, to Commence Trading on the Nasdaq Capital Market on <chron>October 31, 2025</chron> under the Ticker Symbol "NCEL"</p> <p> <span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location> and NESS ZIONA, Israel </span>, <span class="legendSpanClass"><chron>Oct. 30, 2025</chron></span> /PRNewswire/ -- </p> http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+Ltd.+and+Kadimastem+Ltd.+Announce+Completion+of+Merger/25530766.html Thu, 30 Oct 2025 16:15:00 -0500 NCEL NCEL NLS NLSP NLSPW O.23415075 http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+Ltd.+and+Kadimastem+Ltd.+Announce+Completion+of+Merger/25530766.html <div class="xn-content"> <p class="prntac"><span>Combined Company Re-Named NewcelX Ltd.</span>, to Commence Trading on the Nasdaq Capital Market on <chron>October 31, 2025</chron> under the Ticker Symbol "NCEL"</p> <p> <span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location> and NESS ZIONA, Israel </span>, <span class="legendSpanClass"><chron>Oct. 30, 2025</chron></span> /PRNewswire/ -- </p> http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+Ltd.+and+Kadimastem+Ltd.+Announce+Completion+of+Merger/25530766.html Thu, 30 Oct 2025 16:15:00 -0500 NCEL NCEL NLS NLSP NLSPW O.23415075 http://www.streetinsider.com/PRNewswire/NLS+Pharmaceutics+Ltd.+and+Kadimastem+Ltd.+Announce+Completion+of+Merger/25530766.html <div class="xn-content"> <p class="prntac"><span>Combined Company Re-Named NewcelX Ltd.</span>, to Commence Trading on the Nasdaq Capital Market on <chron>October 31, 2025</chron> under the Ticker Symbol "NCEL"</p> <p> <span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location> and NESS ZIONA, Israel </span>, <span class="legendSpanClass"><chron>Oct. 30, 2025</chron></span> /PRNewswire/ -- </p> http://www.streetinsider.com/PRNewswire/NLS+Pharmaceutics+Ltd.+and+Kadimastem+Ltd.+Announce+Completion+of+Merger/25530766.html Thu, 30 Oct 2025 16:15:00 -0500 NCEL NCEL NLS NLSP NLSPW O.23415075 http://www.streetinsider.com/PRNewswire/NLS+Pharmaceutics+Ltd.+and+Kadimastem+Ltd.+Announce+Completion+of+Merger/25530766.html <div class="xn-content"> <p class="prntac"><span>Combined Company Re-Named NewcelX Ltd.</span>, to Commence Trading on the Nasdaq Capital Market on <chron>October 31, 2025</chron> under the Ticker Symbol "NCEL"</p> <p> <span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location> and NESS ZIONA, Israel </span>, <span class="legendSpanClass"><chron>Oct. 30, 2025</chron></span> /PRNewswire/ -- </p> http://www.streetinsider.com/PRNewswire/NLS+Pharmaceutics+Ltd.+and+Kadimastem+Ltd.+Announce+Completion+of+Merger/25530766.html Thu, 30 Oct 2025 16:15:00 -0500 NCEL NCEL NLS NLSP NLSPW O.23415075 http://www.streetinsider.com/PRNewswire/NLS+Pharmaceutics+Ltd.+and+Kadimastem+Ltd.+Announce+Completion+of+Merger/25530766.html <div class="xn-content"> <p class="prntac"><span>Combined Company Re-Named NewcelX Ltd.</span>, to Commence Trading on the Nasdaq Capital Market on <chron>October 31, 2025</chron> under the Ticker Symbol "NCEL"</p> <p> <span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location> and NESS ZIONA, Israel </span>, <span class="legendSpanClass"><chron>Oct. 30, 2025</chron></span> /PRNewswire/ -- </p> http://www.streetinsider.com/PRNewswire/NLS+Pharmaceutics+Ltd.+and+Kadimastem+Ltd.+Announce+Completion+of+Merger/25530766.html Thu, 30 Oct 2025 16:15:00 -0500 NCEL NCEL NLS NLSP NLSPW O.23415075 http://www.streetinsider.com/PRNewswire/NLS+Pharmaceutics+Ltd.+and+Kadimastem+Ltd.+Announce+Completion+of+Merger/25530766.html <div class="xn-content"> <p class="prntac"><span>Combined Company Re-Named NewcelX Ltd.</span>, to Commence Trading on the Nasdaq Capital Market on <chron>October 31, 2025</chron> under the Ticker Symbol "NCEL"</p> <p> <span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location> and NESS ZIONA, Israel </span>, <span class="legendSpanClass"><chron>Oct. 30, 2025</chron></span> /PRNewswire/ -- </p> http://www.streetinsider.com/PRNewswire/NLS+Pharmaceutics+Ltd.+and+Kadimastem+Ltd.+Announce+Completion+of+Merger/25530766.html Thu, 30 Oct 2025 16:15:00 -0500 NCEL NCEL NLS NLSP NLSPW O.23415075 http://www.streetinsider.com/PRNewswire/NLS+Pharmaceutics+Ltd.+and+Kadimastem+Ltd.+Announce+Completion+of+Merger/25530766.html <div class="xn-content"> <p class="prntac"><span>Combined Company Re-Named NewcelX Ltd.</span>, to Commence Trading on the Nasdaq Capital Market on <chron>October 31, 2025</chron> under the Ticker Symbol "NCEL"</p> <p> <span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location> and NESS ZIONA, Israel </span>, <span class="legendSpanClass"><chron>Oct. 30, 2025</chron></span> /PRNewswire/ -- </p> http://www.streetinsider.com/PRNewswire/NLS+Pharmaceutics+Ltd.+and+Kadimastem+Ltd.+Announce+Completion+of+Merger/25530766.html Thu, 30 Oct 2025 16:15:00 -0500 NCEL NCEL NLS NLSP NLSPW O.23415075 http://www.streetinsider.com/PRNewswire/NLS+Pharmaceutics+Ltd.+and+Kadimastem+Ltd.+Announce+Completion+of+Merger/25530766.html <div class="xn-content"> <p class="prntac"><span>Combined Company Re-Named NewcelX Ltd.</span>, to Commence Trading on the Nasdaq Capital Market on <chron>October 31, 2025</chron> under the Ticker Symbol "NCEL"</p> <p> <span class="legendSpanClass"><location value="LU/ch..zurich" idsrc="xmltag.org" >ZURICH</location> and NESS ZIONA, Israel </span>, <span class="legendSpanClass"><chron>Oct. 30, 2025</chron></span> /PRNewswire/ -- </p> http://www.streetinsider.com/PRNewswire/NLS+Pharmaceutics+Ltd.+and+Kadimastem+Ltd.+Announce+Completion+of+Merger/25530766.html Thu, 30 Oct 2025 16:15:00 -0500 NCEL NCEL NLS NLSP NLSPW O.23415075 http://www.streetinsider.com/Corporate+News/NLS+Pharmaceutics+adds+AEX-6xx+compounds+to+CNS+drug+pipeline/25524921.html <p>NLS Pharmaceutics Ltd. (NASDAQ: NLSP) announced the expansion of its DOXA platform with the AEX-6xx series, a collection of small molecules developed by Aexon Labs targeting arousal stability, cognition, and neuroprotection.</p><p>The AEX-6xx series consists of dihydroquinazoline and dihydrobenzothiazine derivatives that combine dual orexin receptor agonism with cathepsin H inhibition. AEX-635, identified as a lead compound, also modulates Multidrug Resistance-Associated Protein 1, which the companies state may enhance neuroprotective effects and improve central nervous system drug bioavailability.</p><p>According to the company's press release, preclinical studies showed up to 80% reduction in cataplexy and greater than 70% increase in wakefulness in orexin knockout http://www.streetinsider.com/Corporate+News/NLS+Pharmaceutics+adds+AEX-6xx+compounds+to+CNS+drug+pipeline/25524921.html Thu, 30 Oct 2025 07:01:17 -0500 NLSP NLSPW http://www.streetinsider.com/Corporate+News/NLS+Pharmaceutics+adds+AEX-6xx+compounds+to+CNS+drug+pipeline/25524921.html <p>NLS Pharmaceutics Ltd. (NASDAQ: NLSP) announced the expansion of its DOXA platform with the AEX-6xx series, a collection of small molecules developed by Aexon Labs targeting arousal stability, cognition, and neuroprotection.</p><p>The AEX-6xx series consists of dihydroquinazoline and dihydrobenzothiazine derivatives that combine dual orexin receptor agonism with cathepsin H inhibition. AEX-635, identified as a lead compound, also modulates Multidrug Resistance-Associated Protein 1, which the companies state may enhance neuroprotective effects and improve central nervous system drug bioavailability.</p><p>According to the company's press release, preclinical studies showed up to 80% reduction in cataplexy and greater than 70% increase in wakefulness in orexin knockout http://www.streetinsider.com/Corporate+News/NLS+Pharmaceutics+adds+AEX-6xx+compounds+to+CNS+drug+pipeline/25524921.html Thu, 30 Oct 2025 07:01:17 -0500 NLSP NLSPW http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+Expands+CNS+Pipeline+With+AEX-6xx+Series+Developed+by+Aexon+Labs/25524891.html <div class="xn-content"> <ul type="disc"> <li> <b>DOXA Platform Expansion Strengthens Cognitive, Arousal, and Neuroprotective Programs</b> </li> http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+Expands+CNS+Pipeline+With+AEX-6xx+Series+Developed+by+Aexon+Labs/25524891.html Thu, 30 Oct 2025 07:00:00 -0500 A.50215973 NLSP NLSPW NLSPW O.07146130 O.23415075 http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+Expands+CNS+Pipeline+With+AEX-6xx+Series+Developed+by+Aexon+Labs/25524891.html <div class="xn-content"> <ul type="disc"> <li> <b>DOXA Platform Expansion Strengthens Cognitive, Arousal, and Neuroprotective Programs</b> </li> http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+Expands+CNS+Pipeline+With+AEX-6xx+Series+Developed+by+Aexon+Labs/25524891.html Thu, 30 Oct 2025 07:00:00 -0500 A.50215973 NLSP NLSPW NLSPW O.07146130 O.23415075 http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+Expands+CNS+Pipeline+With+AEX-6xx+Series+Developed+by+Aexon+Labs/25524891.html <div class="xn-content"> <ul type="disc"> <li> <b>DOXA Platform Expansion Strengthens Cognitive, Arousal, and Neuroprotective Programs</b> </li> http://www.streetinsider.com/Press+Releases/NLS+Pharmaceutics+Expands+CNS+Pipeline+With+AEX-6xx+Series+Developed+by+Aexon+Labs/25524891.html Thu, 30 Oct 2025 07:00:00 -0500 A.50215973 NLSP NLSPW NLSPW O.07146130 O.23415075